SCHEMBL1667129

SCHEMBL1667129

O=S(=O)(Nc1ccccn1)c1ccccc1

nearest known ligand 0.75

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.75
LMNA P02545 4/20 0.75
SMN1; SMN2 Q16637 1/20 0.75
POLB P06746 2/20 0.71
ALDH1A1 P00352 4/20 0.69
HSD11B1 P28845 1/20 0.63
MAPK1 P28482 2/20 0.61
HSD17B10 Q99714 1/20 0.61
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
GAA P10253 1/20 0.60
HTT P42858 1/20 0.60
BRD4 O60885 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30209688 0.90 HSD11B1 (0.74) KDM4ELMNASMN1; SMN2POLBALDH1A1
SCHEMBL13962914 0.86 ALDH1A1 (0.74) KDM4ELMNASMN1; SMN2POLBALDH1A1
SCHEMBL18560174 0.86 KDM4E (0.71) KDM4ELMNASMN1; SMN2POLBALDH1A1
SCHEMBL3296049 0.86 KDM4E (0.67) KDM4ELMNASMN1; SMN2POLBALDH1A1
Sulfapyridine SCHEMBL44219 0.86 SMN1; SMN2 (1.00) KDM4ELMNASMN1; SMN2POLBALDH1A1
SCHEMBL8067195 0.86 KDM4E (0.71) KDM4ELMNASMN1; SMN2POLBALDH1A1
SCHEMBL15215659 0.86 POLB (0.72) KDM4ELMNASMN1; SMN2POLBALDH1A1
Sulfapyridine SCHEMBL29438089 0.86 SMN1; SMN2 (1.00) KDM4ELMNASMN1; SMN2POLBALDH1A1
Sulfapyridine SCHEMBL668918 0.84 SMN1; SMN2 (0.97) KDM4ELMNASMN1; SMN2POLBALDH1A1
Sulfapyridine SCHEMBL11706483 0.84 SMN1; SMN2 (0.97) KDM4ELMNASMN1; SMN2POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115521248-B Chiral alpha-aminomalonate compound containing N-pyridyl benzenesulfonamide, preparation method and application 贵州理工学院 2024-04-05 CN claimed
CN-115521248-A Chiral alpha-amino malonate compounds containing N-pyridyl benzene sulfonamide, and preparation method and application thereof 贵州理工学院 2022-12-27 CN claimed
CN-115124459-A Method for selectively nitrating N- (2-pyridyl) benzene sulfonamide compound 宁波大学 2022-09-30 CN claimed
WO-2022046682-A1 BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) INHIBITOR COMPOSITIONS AND METHODS THEREOF FOR USE AS ANTI-AGING AGENTS MDI BIOLOGICAL LABORATORY (US) 2022-03-03 WO claimed
CN-103739600-B A kind of method of synthesis of cyclic amidine compound SUN YAT-SEN UNIVERSITY (CN) 2016-02-03 CN claimed
CN-103739600-A A novel method for synthesizing cycle amidine compound UNIV SUN YAT SEN 2014-04-23 CN claimed
US-8354407-B2 2-anilino-4-(heterocyclic)amino-pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-15 US claimed
EP-2488503-A1 AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON Myrexis, Inc. (US) 2012-08-22 EP claimed
WO-2011046970-A1 AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON MYREXIS, INC. (US) 2011-04-21 WO claimed
US-20090227586-A1 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-10 US claimed
CN-101506175-A 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha BOEHRINGER INGELHEIM INT (DE) 2009-08-12 CN claimed
EP-2054392-A2 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES AS INHIBITORS OF PROTEIN KINASE C-ALPHA Boehringer Ingelheim International GmbH (DE) 2009-05-06 EP claimed
WO-2007146981-A2 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES AS INHIBITORS OF PROTEIN KINASE C-ALPHA BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-12-21 WO claimed
US-20070293494-A1 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines DJUNG JANE F 2007-12-20 US claimed
EP-1599477-A1 SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-11-30 EP claimed
WO-2004074288-A1 SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-09-02 WO claimed
EP-3713918-B1 SULFASALAZINE SALTS, PRODUCTION PROCESSES AND USES MEDAC GES FUER KLINISCHE SPEZIALPRAEPARATE MBH (DE) 2025-07-23 EP disclosed
US-12274706-B2 Pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production process and use MEDAC GESELLSCHAFT FUER KLINISCHE (DE) 2025-04-15 US disclosed
CN-1088918-A The salicylic acid compounds of new replacement KABI PHARMACIA AB (SE) 1994-07-06 CN disclosed
US-4186019-A SULFONAMIDOPYRIDINES, SILVER HALIDE AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) 1980-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293494-A1 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines PRKCA, PRKCG, PRKCH KDM4E 981/4885LMNA 1437/4885SMN1; SMN2 3836/4885
US-20090227586-A1 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES PRKCA, PRKCG, PRKCH KDM4E 981/4885LMNA 1437/4885SMN1; SMN2 3836/4885
US-12274706-B2 Pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production process and use SI, SOST, SLC10A2 KDM4E 4632/4885LMNA 4858/4885SMN1; SMN2 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.